Spero Therapeutics Statistics
Share Statistics
Spero Therapeutics has 54.52M shares outstanding. The number of shares has increased by 1.2% in one year.
| Shares Outstanding | 54.52M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.87% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 39.50M |
| Failed to Deliver (FTD) Shares | 2.91K |
| FTD / Avg. Volume | 1.01% |
Short Selling Information
The latest short interest is 625.19K, so 1.15% of the outstanding shares have been sold short.
| Short Interest | 625.19K |
| Short % of Shares Out | 1.15% |
| Short % of Float | 1.58% |
| Short Ratio (days to cover) | 2.08 |
Valuation Ratios
The PE ratio is 3.4 and the forward PE ratio is -1.17.
| PE Ratio | 3.4 |
| Forward PE | -1.17 |
| PS Ratio | 0.8 |
| Forward PS | 40.5 |
| PB Ratio | 0.72 |
| P/FCF Ratio | -2.35 |
| PEG Ratio | n/a |
Enterprise Valuation
Spero Therapeutics Inc. has an Enterprise Value (EV) of 6.68M.
| EV / Earnings | 0.29 |
| EV / Sales | 0.07 |
| EV / EBITDA | 0.26 |
| EV / EBIT | 0.31 |
| EV / FCF | -0.2 |
Financial Position
The company has a current ratio of 3.53, with a Debt / Equity ratio of 0.
| Current Ratio | 3.53 |
| Quick Ratio | 3.53 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is 0.21% and return on capital (ROIC) is 17.15%.
| Return on Equity (ROE) | 0.21% |
| Return on Assets (ROA) | 0.13% |
| Return on Capital (ROIC) | 17.15% |
| Revenue Per Employee | 2.10M |
| Profits Per Employee | 495.78K |
| Employee Count | 46 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 2.60M |
| Effective Tax Rate | 0.1 |
Stock Price Statistics
The stock price has increased by -33.56% in the last 52 weeks. The beta is 0.63, so Spero Therapeutics 's price volatility has been higher than the market average.
| Beta | 0.63 |
| 52-Week Price Change | -33.56% |
| 50-Day Moving Average | 1.13 |
| 200-Day Moving Average | 1.33 |
| Relative Strength Index (RSI) | 39.47 |
| Average Volume (20 Days) | 289.04K |
Income Statement
In the last 12 months, Spero Therapeutics had revenue of 96.73M and earned 22.81M in profits. Earnings per share was 0.43.
| Revenue | 96.73M |
| Gross Profit | 96.37M |
| Operating Income | 21.48M |
| Net Income | 22.81M |
| EBITDA | 25.77M |
| EBIT | 21.48M |
| Earnings Per Share (EPS) | 0.43 |
Balance Sheet
The company has 76.33M in cash and 5.54M in debt, giving a net cash position of 70.79M.
| Cash & Cash Equivalents | 76.33M |
| Total Debt | 5.54M |
| Net Cash | 70.79M |
| Retained Earnings | -391.07M |
| Total Assets | 135.16M |
| Working Capital | 82.53M |
Cash Flow
In the last 12 months, operating cash flow was -32.99M and capital expenditures 0, giving a free cash flow of -32.99M.
| Operating Cash Flow | -32.99M |
| Capital Expenditures | 0 |
| Free Cash Flow | -32.99M |
| FCF Per Share | -0.63 |
Margins
Gross margin is 99.62%, with operating and profit margins of 22.21% and 23.58%.
| Gross Margin | 99.62% |
| Operating Margin | 22.21% |
| Pretax Margin | 26.26% |
| Profit Margin | 23.58% |
| EBITDA Margin | 26.64% |
| EBIT Margin | 22.21% |
| FCF Margin | -34.11% |
Dividends & Yields
SPRO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 44.33% |
| FCF Yield | -62.7% |
Analyst Forecast
The average price target for SPRO is $5, which is 415.5% higher than the current price. The consensus rating is "Hold".
| Price Target | $5 |
| Price Target Difference | 415.5% |
| Analyst Consensus | Hold |
| Analyst Count | 4 |
Scores
| Altman Z-Score | -2.65 |
| Piotroski F-Score | 3 |